Get the latest Science News and Discoveries
Tarlatamab with anti-PD-L1 as first-line maintenance after chemo-immunotherapy for ES-SCLC demonstrates acceptable safety profile and unprecedented overall survival - EurekAlert!
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
None
Or read this on Eureka Alert